www.tarozzi.net

Argomenti e Notizie
sull'Osteoporosi
con raccolte
bibliografiche su

a cura del
Dott. C.Tarozzi
Bologna

Anno 21^°
Num. 132
Recens. 2579

questo sito aderisce fin dal 2004 allo standard HONcode per l'affidabilità dell'informazione medica. Verifica qui.

Rassegna - Alimenti e Calcio - Questionari - T-Score - Valore di un Test - Calcolatori - Contatti - Digitalia - Radioactivity

Ricerca nell'archivio di questo sito... ?

Nuova bibliografia selezionata fino al mese di settembre 2016 (recensioni 22)

Ordina per Autore - Titolo - Rivista

Kyriakos G, Vidal-Casariego A, Quiles-Sánchez LV, Calleja-Fernández A, Ávila-Turcios D, Urosa-Maggi JA, Ballesteros-Pomar MD, Cano-Rodríguez I.
A comparative study between the implementation of the FRIDEX calibration and the NOGG guideline in the management of osteoporosis in routine clinical practice.
Reumatol Clin. 2016 Jun 28. pii: S1699-258X(16)30051-1.

Pichardo SE, Kuijpers SC, Van Merkesteyn JP.
Bisphosphonate-related osteonecrosis of the jaws: Cohort study of surgical treatment results in seventy-four stage II/III patients.
J Craniomaxillofac Surg. 2016 Jun 23. pii: S1010-5182(16)30104-4.

Agarwala S, Agashe VM, Shetty V, Mohrir G, Moonot P.
Caveats of bisphosphonate abuse.
Indian J Orthop. 2016 Jul-Aug;50(4):434-9.

Kjellberg J, Jorgensen AD, Vestergaard P, Ibsen R, Gerstoft F, Modi A.
Cost and health care resource use associated with noncompliance with oral bisphosphonate therapy: an analysis using Danish health registries.
Osteoporos Int. 2016 Jul 9.

Zhao C, Hou H, Chen Y, Lv K.
Effect of aerobic exercise and raloxifene combination therapy on senile osteoporosis.
J Phys Ther Sci. 2016 Jun;28(6):1791-4.

Genant HK, Engelke K, Bolognese MA, Mautalen C, Brown JP, Recknor C, Goemaere S, Fuerst T, Yang YC, Grauer A, Libanati C.
Effects of Romosozumab Compared with Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women with Low Bone Mass.
J Bone Miner Res. 2016 Aug 3.

Sheibani-Rad S.
Femoral Fractures Following Long-term Bisphosphonate Use.
Orthopedics. 2016 Aug 18:1-5.

Akarirmak Ü, Koçyigit H, Eskiyurt N, Esmaeilzadeh S, Kuru Ö, Yalçinkaya EY, Peker Ö, Ekim AA, Özgirgin N, Çalis M, Rezvani A, Çevikol A, Eyigör S, Sendur ÖF, Irdesel J; INSTRUCT Study Group.
Influence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: An observational study in Turkish patients with postmenopausal osteoporosis.
Acta Orthop Traumatol Turc. 2016 Aug 11.

Lipold LD, Batur P, Kagan R.
Is there a time limit for systemic menopausal hormone therapy?
Cleve Clin J Med. 2016 Aug;83(8):605-12.

Iizuka Y, Takechi R, Iizuka H, Omodaka T, Takagishi K.
Localized cortical thickening of the femoral diaphysis captured on an X-ray before alendronate therapy in two cases of atypical femoral fracture.
Skeletal Radiol. 2016 Oct;45(10):1403-7.

Popescu D, Trandabat C, Puha B, Veliceasa B, Alexa O.
MANAGEMENT OF BILATERAL FEMORAL NECK FRACTURE IN A NONAGENARIAN PATIENT--CASE REPORT.
Rev Med Chir Soc Med Nat Iasi. 2016 Apr-Jun;120(2):376-9.

Lain R, Ajwani S.
Minor post-extraction complications other than BRONJ in older patients on oral bisphosphonates - a retrospective study.
Gerodontology. 2016 Jul 19.

Chan CK, Mason A, Cooper C, Dennison E.
Novel advances in the treatment of osteoporosis.
Br Med Bull. 2016 Aug 24. [Epub ahead of print] Review.

Milat F, Ebeling PR.
Osteoporosis treatment: a missed opportunity.
Med J Aust. 2016 Aug 15;205(4):185-90.

Pazianas M, Abrahamsen B.
Osteoporosis treatment: bisphosphonates reign to continue for a few more years, at least?
Ann N Y Acad Sci. 2016 Aug 15.

Moore AE, Renton T, Taylor T, Popat S, Jasani MK.
Relevance of Bisphosphonate Therapy in Osteoporosis and Cancer--No Cause for Alarm in Dentistry.
Dent Update. 2016 Apr;43(3):235-6, 239-40, 242.

Higgins M, Morgan-John S, Badhe S.
Simultaneous, bilateral, complete atypical femoral fractures after long-term alendronate use.
J Orthop. 2016 Aug 12;13(4):401-3

Ward J, Wood C, Rouch K, Pienkowski D, Malluche HH.
Stiffness and strength of bone in osteoporotic patients treated with varying durations of oral bisphosphonates.
Osteoporos Int. 2016 Sep;27(9):2681-8.

María RS, Marta PM, Sonia S, Natalia GG, Tamara M, Ignasi T, Maria MG, Jaime RM, Adolfo DP, Joan A, Xavier N.
TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.
Bone. 2016 Aug 9;92:1-8

Su Y, Leung J, Hans D, Lamy O, Kwok T.
The added value of trabecular bone score to FRAX^® to predict major osteoporotic fractures for clinical use in Chinese older people: the Mr. OS and Ms. OS cohort study in Hong Kong.
Osteoporos Int. 2016 Aug 26. [Epub ahead of print]

Wozniak LA, Johnson JA, McAlister FA, Beaupre LA, Bellerose D, Rowe BH, Majumdar SR.
Understanding fragility fracture patients' decision-making process regarding bisphosphonate treatment.
Osteoporos Int. 2016 Jul 16.

Hamano T, Nakano C.
[Is denosmab really effective and safe in the care of CKD-MBD?].
Clin Calcium. 2016 Sep;26(9):1309-17.

(Vers. 2.1) Modificato il 11-9-2016

http://www.tarozzi.net